Literature DB >> 29635781

Interaction among variants in the SLC gene family (SLC6A14, SLC26A9, SLC11A1, and SLC9A3) and CFTR mutations with clinical markers of cystic fibrosis.

Stephanie V N Pereira1, Jose D Ribeiro2,3, Carmen S Bertuzzo1, Fernando A L Marson1,2,3.   

Abstract

BACKGROUND: Cystic fibrosis (CF) is due to dysfunction of the CFTR channel and function of this channel is, in turn, affected by modifier genes that can impact the clinical phenotype. In this context, we analyzed the interaction among rs3788766*SLC6A14, rs7512462*SLC26A9, rs17235416*SLC11A1, and rs17563161*SLC9A3 variants, CFTR mutations and 40 CF severity markers by the Multifactor Dimensionality Reduction (MDR) model.
METHODS: A total of 164 patients with CF were included in the study. The variants in the modifier genes were identified by real-time PCR and the genotype of the CFTR gene in the diagnostic routine. Analysis of interaction between variants, CFTR mutations groupings and demographic, clinical and laboratory data were performed by the MDR.
RESULTS: There were interaction between the rs3788766, rs7512462, rs17235416, and rs17563161 variants, and CFTR mutations with pancreatic insufficiency (PI), onset of digestive symptoms, and presence of mucoid Pseudomonas aeruginosa. Regarding PI, the interaction was observed for CFTR*rs17563161 (P-value = 0.015). Also, for onset of digestive symptoms the interaction was observed for CFTR*rs3788766*rs7512462*rs17235416*rs17563161 (P-value = 0.036). Considering the presence of mucoid P. aeruginosa, the interaction occurred for CFTR*rs3788766*rs7512462*rs17563161 (P-value = 0.035).
CONCLUSION: Interaction between variants in the SLC family genes and the grouping for CFTR mutations were associated with PI, onset of digestive symptoms and mucoid P. aeruginosa, being important to determine one of the factors that may cause the diversity among the patients with CF.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  CFTR; rs17235416; rs17563161; rs3788766; rs7512462

Mesh:

Substances:

Year:  2018        PMID: 29635781     DOI: 10.1002/ppul.24005

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

Review 1.  SLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease.

Authors:  Giulia Gorrieri; Federico Zara; Paolo Scudieri
Journal:  Biomolecules       Date:  2022-01-25

2.  Genetic Variation Near chrXq22-q23 Is Linked to Emotional Functioning in Cystic Fibrosis.

Authors:  Eric Barbato; Barbara Daly; Sara Douglas; Mary Kerr; Paul Litman; Rebecca Darrah
Journal:  Biol Res Nurs       Date:  2020-05-11       Impact factor: 2.522

Review 3.  Physiological and Pathophysiological Relevance of the Anion Transporter Slc26a9 in Multiple Organs.

Authors:  Xuemei Liu; Taolang Li; Biguang Tuo
Journal:  Front Physiol       Date:  2018-08-28       Impact factor: 4.566

Review 4.  Cystic Fibrosis-Related Diabetes (CFRD): Overview of Associated Genetic Factors.

Authors:  Fernanda Iafusco; Giovanna Maione; Francesco Maria Rosanio; Enza Mozzillo; Adriana Franzese; Nadia Tinto
Journal:  Diagnostics (Basel)       Date:  2021-03-22

5.  Proteome profile of patients with excellent and poor speech intelligibility after cochlear implantation: Can perilymph proteins predict performance?

Authors:  Martin Durisin; Caroline Krüger; Andreas Pich; Athanasia Warnecke; Melanie Steffens; Carsten Zeilinger; Thomas Lenarz; Nils Prenzler; Heike Schmitt
Journal:  PLoS One       Date:  2022-03-03       Impact factor: 3.240

6.  Expression of SLC26A9 in Airways and Its Potential Role in Asthma.

Authors:  Jiraporn Ousingsawat; Raquel Centeio; Rainer Schreiber; Karl Kunzelmann
Journal:  Int J Mol Sci       Date:  2022-03-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.